2025-05-28-Jefferies-生成式人工智能在药物发现和精准医学中的应用_7页_197kb

Summary of INVITE Applications of Generative AI in Drug Discovery and Precision Medicine

Core Content

This document is an INVITE from Jefferies to a webinar on the applications of Generative AI in drug discovery and precision medicine. The event is scheduled for Thursday, May 29, 2025, at 2:00 PM ET. It highlights the transformative potential of AI in accelerating drug development and enabling personalized medicine.

Main Points

• AI in Drug Discovery:

  • AI can significantly reduce the time and cost of traditional drug development processes.
  • It helps in target identification, high-throughput screening, hit generation, and lead identification.
  • Generative AI is expected to shorten the time from bench to clinic and improve the success rate of drug development.

• AI in Precision Medicine:

  • AI enhances personalized diagnosis and treatment by analyzing large volumes of patient data.
  • It enables early detection, continuous disease monitoring, and tailored therapy selection.
  • This leads to better patient outcomes across the care continuum.

• Webinar Speakers:

  • The webinar will be presented by Jefferies analysts specializing in biotech, life science, and diagnostic tools.
  • Key speakers include:
    • Michael Yee
    • Akash Tewari
    • Tycho Peterson
    • Andrew Tsai
    • Dennis Ding

• Relevant Companies and Tickers:

  • The report discusses several companies that are leveraging AI in drug discovery and precision medicine.
  • Some of the highlighted tickers include:
    • ACRV (Acrivon Therapeutics Inc.)
    • ANRO (Alto Neuroscience, Inc.)
    • DHR (Danaher Corp.)
    • GLUE (Monte Rosa Therapeutics)
    • IDYA (Ideaya Biosciences)
    • ILMN (Illumina, Inc.)
    • RXRX (Recursion Pharmaceuticals, Inc.)
    • RLAY (Relay Therapeutics, Inc.)
    • WGS (GeneDx)
    • XtalPi (2228.HK)

• Investment Ratings and Price Targets:

  • Jefferies provides investment ratings (Buy, Hold, Underperform) and price targets for the mentioned companies.
  • For example:
    • ACRV: $1.10, BUY
    • ANRO: $2.87, BUY
    • DHR: $189.18, BUY
    • WGS: $69.99, BUY
    • IDYA: $19.42, BUY
    • ILMN: $82.49, HOLD
    • RXRX: $4.39, HOLD
    • RLAY: $2.85, BUY
    • XtalPi (2228.HK): HK$4.60, BUY

• Valuation Methodology:

  • Ratings are based on factors such as market capitalization, growth, volatility, and expected total return.
  • Price targets are derived from various financial models including DCF, EBITDA, P/E, and others.

• Risks and Disclosures:

  • The report acknowledges potential conflicts of interest due to Jefferies' investment banking activities with the companies mentioned.
  • Investors are advised to consider this report as one of many factors in their investment decisions.
  • The report is not tailored to individual investors and does not constitute investment advice.
  • Jefferies may have a financial interest in some of the companies discussed, and this could affect the objectivity of the report.

• Legal and Regulatory Information:

  • The report is subject to various legal and regulatory disclosures depending on the jurisdiction.
  • Different regions (e.g., US, Canada, UK, Germany, Hong Kong, Singapore, Japan, India, Australia, Dubai) have specific distribution and compliance rules.
  • The report is not intended for retail investors in some regions and is restricted to professional or institutional investors.

Key Information

• Event Details:

  • Date: Thursday, May 29, 2025
  • Time: 2:00 PM ET
  • Location: Virtual (no physical location mentioned)
  • Purpose: To discuss AI-driven innovations in drug discovery and precision medicine.

• Investment Recommendations:

  • Jefferies provides a list of companies with their respective ratings and price targets.
  • The majority of the companies are rated BUY, while a few are rated HOLD.
  • No companies are rated UNDERPERFORM in the current list.

• Analyst Certification:

  • Each analyst certifies that their views reflect their personal opinions and that their compensation is not tied to the recommendations in the report.

• Franchise Picks:

  • These are stock selections from Jefferies' equity analysts, based on fundamental analysis and investment themes.
  • Only BUY rated stocks are included.
  • Stocks are added or removed based on changing circumstances and performance.

Conclusion

The document underscores the growing role of Generative AI in revolutionizing the pharmaceutical and biotech industries, particularly in drug discovery and precision medicine. It also provides a comprehensive list of companies that are at the forefront of these innovations, along with investment ratings and price targets. The webinar is an opportunity to gain insights from Jefferies analysts on the future of AI in healthcare. Investors are advised to be aware of potential conflicts of interest and to consider the report alongside other investment materials and professional advice.